Drug-resistance or viral-load testing required before switch to dolutegravir in Togo
How do we deal with apparent cases of PrEP failure?
Ibalizumab monoclonal antibody is effective in real-world use
Dramatic decline in proportion of people with extensive resistance to anti-HIV medications
Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART
ADVANCE trial shows dolutegravir is highly effective in South Africa
ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available
Significant health gains from faster switching to second-line ART in sub-Saharan Africa
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs
